RXRX: Recursion Pharmaceuticals, Inc. Stock

by  •  • Comments Off on RXRX: Recursion Pharmaceuticals, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 1,664.57
Enterprise Value ($M) 1,189.15
Book Value ($M) 933.95
Book Value / Share 2.34
Price / Book 1.78
NCAV ($M) 212.86
NCAV / Share 0.53
Price / NCAV 7.82

Profitability (mra)
Return on Invested Capital (ROIC) -0.56
Return on Assets (ROA) -1.03
Return on Equity (ROE) -1.43

Liquidity (mrq)
Quick Ratio 4.11
Current Ratio 4.11

Balance Sheet (mrq) ($M)
Current Assets 584.14
Assets 1,305.23
Liabilities 371.29
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 58.84
Operating Income -479.00
Net Income -463.66

Cash Flow Statement (mra) ($M)
Cash From Operations -359.17
Cash from Investing 260.06
Cash from Financing 304.12

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
04-04 13G Kim Yohan 5.86
02-14 13G/A Ra Capital Management, L.p. 2.00 -49.79
02-14 13G/A ARK Investment Management LLC 8.47 40.17
02-05 13G/A BlackRock, Inc. 6.10 12.99
11-12 13G/A Fmr Llc 3.04 -23.25
11-12 13G/A Vanguard Group Inc 8.82 0.00
11-04 13G/A Kinnevik AB (publ) 4.30 14.42
10-18 13G/A State Street Corp 4.70 5.91

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-05-05 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPOR
2025-02-28 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PUR
2024-11-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-30 5,560,523 18,291,011 30.40
2025-05-29 5,737,909 19,860,981 28.89
2025-05-28 5,688,525 20,905,848 27.21
2025-05-27 4,225,657 20,177,906 20.94

(click for more detail)

Similar Companies
RPRX – Royalty Pharma plc RPTX – Repare Therapeutics Inc.
RVMD – Revolution Medicines, Inc. SANA – Sana Biotechnology, Inc.
SCPH – scPharmaceuticals Inc.


Financial data and stock pages provided by
Fintel.io